Verve Therapeutics, a clinical-stage biotechnology company, is a leading player in the fight against heart disease, leveraging its expertise in cardiovascular medicine, human genetics, and gene editing to develop transformative, once-and-done therapies. The company's unique approach to gene editing, designed to permanently lower LDL cholesterol and triglyceride levels, sets it apart from competitors and positions it at the forefront of precision genetic medicine. With a culture that fosters passion and drive, Verve has been recognized as a "Best Places to Work" by the Boston Globe, demonstrating its commitment to both its mission and its employees.